Drugs facing NCE-1 in 2024

1. List of Avycaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(2 years from now)

US8471025 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(8 years from now)

US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ALLERGAN Heterocyclic compounds as inhibitors of beta-lactamases
Nov, 2026

(3 years from now)

US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally effective amount of avibactam sodium; A method of treating bacterial infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pnenumonia (habp/vabp) patients comprising administering a bactericidally effective amount of avibactam sodium; Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

2. List of Ayvakit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(11 years from now)

US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 9, 2025
New Indication (I) Jun 16, 2024
Orphan Drug Exclusivity (ODE) Jan 9, 2027

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: January, 2024

Market Authorisation Date: 09 January, 2020

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leukemia (mcl)

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Barhemsys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9545426 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(8 years from now)

US10525033 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(8 years from now)

US9889118 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(8 years from now)

US9084765 ACACIA Use of amisulpride as an anti-emetic
Feb, 2034

(11 years from now)

US11357753 ACACIA Rescue treatment of post operative nausea and vomiting
Feb, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

4. List of Byfavo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US10961250 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US9827251 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(8 years from now)

US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(8 years from now)

US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(8 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(8 years from now)

US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(8 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(8 years from now)

US9561236 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Apr, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 6, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

5. List of Dayvigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2025

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage

6. List of Detectnet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160888 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

US10159759 RADIOMEDIX Pet tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

US10383961 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 3, 2025
Orphan Drug Exclusivity (ODE) Sep 3, 2027

Drugs and Companies using COPPER DOTATATE CU-64 ingredient

NCE-1 date: September, 2024

Market Authorisation Date: 03 September, 2020

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

7. List of Dojolvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(2 years from now)

US8697748 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Oct, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 30, 2027
New Chemical Entity Exclusivity (NCE) Jun 30, 2025

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID;ORAL

More Information on Dosage

8. List of Evrysdi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(10 years from now)

US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 7, 2027
New Chemical Entity Exclusivity (NCE) Aug 7, 2025
New Patient Population (NPP) May 27, 2025

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

9. List of Gavreto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10030005 GENENTECH INC Inhibitors of RET
Nov, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 GENENTECH INC RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 4, 2025
Orphan Drug Exclusivity (ODE) Sep 4, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: September, 2024

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy

Dosage: CAPSULE;ORAL

More Information on Dosage

10. List of Gemtesa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8653260 UROVANT Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Apr, 2029

(6 years from now)

US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET;ORAL

More Information on Dosage

11. List of Imcivree drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9458195 RHYTHM Melanocortin receptor ligands
Oct, 2027

(4 years from now)

US8039435 RHYTHM Melanocortin receptor ligands
Oct, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869 RHYTHM Pharmaceutical compositions
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 25, 2027
New Chemical Entity Exclusivity (NCE) Nov 25, 2025
New Indication (I) Jun 16, 2025

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

12. List of Inqovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9567363 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(5 years from now)

US8268800 OTSUKA Certain compounds, compositions and methods
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618075 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 7, 2025
Orphan Drug Exclusivity (ODE) Jul 7, 2027

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

NCE-1 date: July, 2024

Market Authorisation Date: 07 July, 2020

Treatment: Method for inhibiting cytidine deaminase by administering cedazuridine; Method for inhibiting degradation of a cda substrate by administering cedazuridine; Treatment of chronic myelomonocytic leukemia; Treatment of myelodysplastic syndrome

Dosage: TABLET;ORAL

More Information on Dosage

13. List of Isturisa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(3 years from now)

US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(6 years from now)

US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(12 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2025
Orphan Drug Exclusivity (ODE) Mar 6, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: March, 2024

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

14. List of Klisyri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8980890 ALMIRALL Compositions and methods of treating cell proliferation disorders
Dec, 2025

(2 years from now)

US8236799 ALMIRALL Biaryl compositions and methods for modulating a kinase cascade
Dec, 2025

(2 years from now)

US7300931 ALMIRALL Compositions for treating cell proliferation disorders
Feb, 2026

(3 years from now)

US7851470 ALMIRALL Composition and methods for modulating a kinase cascade
Feb, 2029

(6 years from now)

US10669236 ALMIRALL Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Sep, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001 ALMIRALL Compositions for modulating a kinase cascade and methods of use thereof
Dec, 2027

(4 years from now)

US10617693 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(15 years from now)

US11497750 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2025

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 14 December, 2020

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

More Information on Dosage

15. List of Koselugo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(a month from now)

US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Apr, 2024

(1 year, 2 months from now)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(3 years from now)

US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 10, 2025
Orphan Drug Exclusivity (ODE) Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)

Dosage: CAPSULE;ORAL

More Information on Dosage

16. List of Myfembree drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(11 months from now)

US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(1 year, 14 days from now)

US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids
Sep, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025
New Product (NP) May 26, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage

17. List of Nexletol drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 21, 2025

Drugs and Companies using BEMPEDOIC ACID ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 21 February, 2020

Treatment: Use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; Use of nexletol as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease

Dosage: TABLET;ORAL

More Information on Dosage

18. List of Nexlizet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(10 months from now)

US10912751 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 21, 2025
New Product (NP) Feb 26, 2023

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe

Dosage: TABLET;ORAL

More Information on Dosage

19. List of Nurtec Odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314117 BIOHAVEN IRELAND CGRP receptor antagonists
Feb, 2031

(8 years from now)

US8759372 BIOHAVEN IRELAND N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 BIOHAVEN IRELAND Rimegepant for CGRP related disorders
Mar, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 27, 2025
New Indication (I) May 27, 2024

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 27 February, 2020

Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

20. List of Olinvyk drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9309234 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

US11077098 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

US8835488 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 30, 2025

Drugs and Companies using OLICERIDINE ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 30 October, 2020

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

21. List of Ongentys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8907099 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
May, 2027

(4 years from now)

US8168793 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Apr, 2029

(6 years from now)

US9630955 NEUROCRINE Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Jul, 2026

(3 years from now)

US9745290 NEUROCRINE Dosage regimen for COMT inhibitors
Oct, 2027

(4 years from now)

US8524746 NEUROCRINE Dosage regimen for COMT inhibitors
Jul, 2029

(6 years from now)

US10583130 NEUROCRINE Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(7 years from now)

US10071085 NEUROCRINE Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(7 years from now)

US10357468 NEUROCRINE Medicaments for slowing Parkinson's disease
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Method of inhibiting comt in the periphery; Method of treating parkinson's disease; Method of reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage

22. List of Orgovyx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(11 months from now)

US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(1 year, 1 day from now)

US10350170 MYOVANT SCIENCES Solid preparation
Feb, 2036

(13 years from now)

US10449191 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

US10786501 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

23. List of Orladeyo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(12 years from now)

US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11230530 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US10689346 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 3, 2027
New Chemical Entity Exclusivity (NCE) Dec 3, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage

24. List of Oxlumo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(12 years from now)

US11446380 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Oct, 2035

(12 years from now)

US11261447 ALNYLAM PHARMS INC Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Nov, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 23, 2027
New Chemical Entity Exclusivity (NCE) Nov 23, 2025
New Indication (I) Oct 6, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

25. List of Pemazyre drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jun, 2033

(10 years from now)

US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Apr 17, 2027
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg to about 10 mg of pemigatinib; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib qd for 14 days then not administering pemigatinib for 7 days in a 21-day cycle; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg

Dosage: TABLET;ORAL

More Information on Dosage

26. List of Pizensy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10806743 BRAINTREE LABS Method of administering lactitol to reduce plasma concentration of lactitol
May, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2025

Drugs and Companies using LACTITOL ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 12 February, 2020

Treatment: Method of treating chronic idiopathic constipation in adult patients.

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

27. List of Qinlock drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188113 DECIPHERA PHARMS Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jul, 2030

(7 years from now)

US8461179 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48731 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(9 years from now)

US11344536 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11433056 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11426390 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US10966966 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11266635 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11395818 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(17 years from now)

US11185535 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 15, 2025
Orphan Drug Exclusivity (ODE) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumor; Treatment of gastrointestinal stromal tumors in patients suffering from hypertension; Method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily; Treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor; Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib; Treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome

Dosage: TABLET;ORAL

More Information on Dosage

28. List of Retevmo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112942 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(14 years from now)

US10584124 LOXO ONCOLOGY INC Crystalline forms
Oct, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10172851 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(14 years from now)

US10137124 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Oct, 2037

(14 years from now)

US10786489 LOXO ONCOLOGY INC Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 8, 2025
Orphan Drug Exclusivity (ODE) May 8, 2027

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 08 May, 2020

Treatment: Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate); Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is papillary thyroid cancer; The treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is recurrent thyroid cancer; Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is medullary thyroid cancer; The treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer (nsclc); Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is differentiated thyroid cancer; Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive refractory differentiated thyroid cancer who require systemic therapy and are radioactive iodine-refractory

Dosage: CAPSULE;ORAL

More Information on Dosage

29. List of Reyvow drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Apr, 2025

(2 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Mar, 2023

(a month from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage

30. List of Rukobia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461333 VIIV HLTHCARE Salts of prodrugs of piperazine and substituted piperidine antiviral agents
Feb, 2025

(2 years from now)

US7745625 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents
Nov, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168615 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents
Feb, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 2, 2025

Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient

NCE-1 date: July, 2024

Market Authorisation Date: 02 July, 2020

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

31. List of Tabrecta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7767675 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(4 years from now)

US8461330 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(4 years from now)

US8420645 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
Jun, 2031

(8 years from now)

US10596178 NOVARTIS PHARM Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
Jul, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8901123 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
May, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 6, 2025
Orphan Drug Exclusivity (ODE) May 6, 2027

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 06 May, 2020

Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation

Dosage: TABLET;ORAL

More Information on Dosage

32. List of Tauvid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8932557 AVID RADIOPHARMS INC Imaging agents for detecting neurological dysfunction
May, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2025

Drugs and Companies using FLORTAUCIPIR F-18 ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 28 May, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

33. List of Tazverik drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9090562 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US11052093 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9394283 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US10821113 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US8410088 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Aug, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9175331 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(8 years from now)

US9334527 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(8 years from now)

US9949999 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(8 years from now)

US8691507 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof
Sep, 2031

(8 years from now)

US9333217 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(8 years from now)

US8895245 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof
Sep, 2031

(8 years from now)

US8765732 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9522152 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10420775 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9855275 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9549931 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10155002 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10245269 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US11491163 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US9872862 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US9688665 EPIZYME INC Methods of treating cancer
Aug, 2034

(11 years from now)

US10369155 EPIZYME INC Method for treating cancer
Oct, 2035

(12 years from now)

US9889138 EPIZYME INC Method for treating cancer
Oct, 2035

(12 years from now)

US10786511 EPIZYME INC Method for treating cancer
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 23, 2025
New Indication (I) Jun 18, 2023
Orphan Drug Exclusivity (ODE) Jan 23, 2027

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

NCE-1 date: January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; Method of treating relapsed or refractory follicular lymphoma; Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma; Method of treating epithelioid sarcoma by inhibiting enhancer of zeste homolog 2 (ezh2); Method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2; Method of treating lymphoma; Method of treating sarcoma; Method of treating follicular lymphoma

Dosage: TABLET;ORAL

More Information on Dosage

34. List of Tukysa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7452895 SEAGEN Quinazoline analogs as receptor tyrosine kinase inhibitors
Nov, 2024

(1 year, 9 months from now)

US8648087 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693989 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
May, 2027

(4 years from now)

US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor
Oct, 2032

(9 years from now)

US11504370 SEAGEN NA
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 17, 2027
New Chemical Entity Exclusivity (NCE) Apr 17, 2025

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

35. List of Veklury drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8318682 GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

USRE46762 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

US8008264 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Sep, 2029

(6 years from now)

US10065958 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Sep, 2031

(8 years from now)

US11492353 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Dec, 2031

(8 years from now)

US9724360 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(12 years from now)

US9949994 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007208 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(13 years from now)

US11382926 GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Sep, 2036

(13 years from now)

US10695361 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(13 years from now)

US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

US11266681 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

US11491169 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 22, 2025
New Patient Population (NPP) Apr 25, 2025
New Dosing Schedule (D) Jan 21, 2025

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization and for whom concomitant use of chloroquine, or an analog or sale thereof, is not recommended; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg) and for whom concomitant use of chloroquine, or an analog or salt thereof, is not recommended

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage

36. List of Viltepso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10870676 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(8 years from now)

US9079934 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 12, 2025
Orphan Drug Exclusivity (ODE) Aug 12, 2027

Drugs and Companies using VILTOLARSEN ingredient

NCE-1 date: August, 2024

Market Authorisation Date: 12 August, 2020

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

37. List of Winlevi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143240 SUN PHARM 17α, 21-dihydroxypregnene esters as antiandrogenic agents
Jan, 2023

(21 days ago)

US9211295 SUN PHARM 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2023

(5 months from now)

US8865690 SUN PHARM 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2023

(5 months from now)

US9486458 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2028

(5 years from now)

US10159682 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Aug, 2028

(5 years from now)

US11207332 SUN PHARM Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Nov, 2028

(5 years from now)

US9433628 SUN PHARM Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Feb, 2029

(6 years from now)

US8785427 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

NCE-1 date: August, 2024

Market Authorisation Date: 26 August, 2020

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate

Dosage: CREAM;TOPICAL

More Information on Dosage

38. List of Xcopri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598279 SK LIFE Neurotherapeutic azole compounds
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2025

Drugs and Companies using CENOBAMATE ingredient

NCE-1 date: March, 2024

Market Authorisation Date: 10 March, 2020

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

39. List of Xeglyze drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9839631 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Jul, 2024

(1 year, 5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8212038 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Jul, 2024

(1 year, 5 months from now)

US9357783 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Jul, 2024

(1 year, 5 months from now)

US7812163 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Oct, 2026

(3 years from now)

US10292389 DR REDDYS LABS SA Pediculicidal composition
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 24, 2025

Drugs and Companies using ABAMETAPIR ingredient

NCE-1 date: July, 2024

Market Authorisation Date: 24 July, 2020

Treatment: Topical treatment of head lice infestation in patients 6 months of age and older

Dosage: LOTION;TOPICAL

More Information on Dosage

40. List of Zeposia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8796318 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(6 years from now)

US8481573 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9382217 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(6 years from now)

US10239846 CELGENE INTL Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 27, 2024
New Chemical Entity Exclusivity (NCE) Mar 25, 2025

Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient

NCE-1 date: March, 2024

Market Authorisation Date: 25 March, 2020

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the treatment of moderately to severely active ulcerative colitis

Dosage: CAPSULE;ORAL

More Information on Dosage

41. List of Zepzelca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7763615 JAZZ Ecteinascidin analogs for use as antitumour agents
Dec, 2024

(1 year, 10 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 15, 2025
Orphan Drug Exclusivity (ODE) Jun 15, 2027

Drugs and Companies using LURBINECTEDIN ingredient

NCE-1 date: June, 2024

Market Authorisation Date: 15 June, 2020

Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

42. List of Zokinvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828356 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Oct, 2023

(8 months from now)

US7838531 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Jul, 2024

(1 year, 5 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 20, 2027
New Chemical Entity Exclusivity (NCE) Nov 20, 2025

Drugs and Companies using LONAFARNIB ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 20 November, 2020

Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in